Search Results

DexCom, Inc. will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando.

Tandem Diabetes Care, Inc. and Dexcom, Inc., announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems.

Dexcom, Inc., a global leader in real-time continuous glucose monitoring for people with diabetes, announced that residents of Nova Scotia living with either type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria now have coverage for Dexcom G6 and Dexcom G7 continuous glucose monitoring systems.

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024.

DexCom, Inc., the leader in real-time continuous glucose monitoring for people with diabetes, released its annual Sustainability Report.

DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024.